Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36014
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRichard Kitching A.en
dc.contributor.authorGodfrey A.S.en
dc.contributor.authorOoi J.D.en
dc.contributor.authorO'sullivan K.-M.en
dc.contributor.authorOudin V.en
dc.contributor.authorHoldsworth S.R.en
dc.contributor.authorGan P.-Y.en
dc.date.accessioned2021-05-14T12:12:02Zen
dc.date.available2021-05-14T12:12:02Zen
dc.date.copyright2019en
dc.date.created20190917en
dc.date.issued2019-09-17en
dc.identifier.citationJournal of the American Society of Nephrology. 30 (8) (pp 1365-1374), 2019. Date of Publication: August 2019.en
dc.identifier.issn1046-6673en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36014en
dc.description.abstractBackground Myeloperoxidase (MPO)-ANCA-associated GN is a significant cause of renal failure. Manipulating autoimmunity by inducing regulatory T cells is potentially a more specific and safer therapeutic option than conventional immunosuppression. Methods To generate MPO-specific regulatory T cells, we used a modified protein-conjugating compound, 1-ethyl-3-(3'dimethylaminopropyl)-carbodiimide (ECDI), to couple the immunodominant MPO peptide (MPO409-428) or a control ovalbumin peptide (OVA323-339) to splenocytes and induced apoptosis in the conjugated cells. We then administered MPO-and OVA-conjugated apoptotic splenocytes (MPO-Sps and OVA-Sps, respectively) to mice and compared their effects on development and severity of anti-MPO GN. We induced autoimmunity to MPO by immunizing mice with MPO in adjuvant; to trigger GN, we used low-dose antiglomerular basement membrane globulin, which transiently recruits neutro-phils that deposit MPO in glomeruli. We also compared the effects of transferring CD4+ T cells from mice treated with MPO-Sp or OVA-Sp to recipient mice with established anti-MPO autoimmunity. Results MPO-Sp but not OVA-Sp administration increased MPO-specific, peripherally derived CD4+ Foxp3- type 1 regulatory T cells and reduced anti-MPO autoimmunity and GN. However, in mice depleted of regulatory T cells, MPO-Sp administration did not protect from anti-MPO autoimmunity or GN. Mice with established anti-MPO autoimmunity that received CD4+ T cells transferred from mice treated with MPO-Sp (but not CD4+ T cells transferred from mice treated with OVA-Sp) were protected from anti-MPO autoimmunity and GN, confirming the induction of therapeutic antigen-specific regulatory T cells. Conclusions These findings in a mouse model indicate that administering apoptotic splenocytes conjugated with the immunodominant MPO peptide suppresses anti-MPO GN by inducing antigen-specific tolerance.Copyright © 2019 by the American Society of Nephrology.en
dc.languageEnglishen
dc.languageenen
dc.publisherAmerican Society of Nephrology (E-mail: email@asn-online.org)en
dc.relation.ispartofJournal of the American Society of Nephrologyen
dc.titleApoptotic cell-induced, antigen-specific immunoregulation to treat experimental antimyeloperoxidase GN.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1681/ASN.2018090955en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid31337690 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31337690]en
dc.identifier.source2002545998en
dc.identifier.institution(Gan, Godfrey, Ooi, O'sullivan, Oudin, Richard Kitching, Holdsworth) Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia (Gan, Holdsworth) Department of Immunology, Monash Health, Clayton, VIC, Australia (Richard Kitching, Holdsworth) Department of Nephrology, Monash Health, Clayton, VIC, Australia (Richard Kitching) Department of Pediatric Nephrology, Monash Health, Clayton, VIC, Australiaen
dc.description.addressP.-Y. Gan, Centre for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia. E-mail: Poh-yi.gan@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailGan P.-Y.; Poh-yi.gan@monash.eduen
dc.description.grantNo: 1147388 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australiaen
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptImmunology and Allergy-
Appears in Collections:Articles
Show simple item record

Page view(s)

30
checked on Oct 7, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.